{"id":"bramicar-hct","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Hypokalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bromocriptine is a dopamine D2 receptor agonist that helps regulate prolactin and metabolic function, while hydrochlorothiazide is a thiazide diuretic that reduces blood pressure by decreasing fluid volume and peripheral vascular resistance. The combination targets both metabolic and cardiovascular parameters in hypertensive patients.","oneSentence":"Bramicar HCT is a fixed-dose combination of bromocriptine and hydrochlorothiazide that reduces dopamine antagonism in the hypothalamus while providing diuretic and antihypertensive effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:36.173Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension with metabolic dysfunction"}]},"trialDetails":[{"nctId":"NCT07030101","phase":"PHASE3","title":"A Study to Investigate Efficacy and Safety of a TCA108 in Participants ≥18 Years With Uncontrolled Hypertension","status":"NOT_YET_RECRUITING","sponsor":"EMS","startDate":"2026-11","conditions":"Hypertension","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24668,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bramicar HCT","genericName":"Bramicar HCT","companyName":"EMS","companyId":"ems","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bramicar HCT is a fixed-dose combination of bromocriptine and hydrochlorothiazide that reduces dopamine antagonism in the hypothalamus while providing diuretic and antihypertensive effects. Used for Hypertension with metabolic dysfunction.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}